GMED
$75.60+1.60%
as of close, Oct 2, 2026
☾ AH $75.60 +1.60%
GMED financial statements
The full income statement, balance sheet, and cash-flow statement for Globus Medical Inc. (GMED), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.
Shares outstanding (point-in-time)
2024-06 135.4M2024-09 136.2M2024-12 137.5M2025-03 135.4M2025-06 135.1M2025-09 133.8M2025-12 135.3M2026-03 135.7M2026-06 134.3M-0.8% over 8 periods
SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.
As-reported fiscal years.
| Line item | Trend | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Income Statement | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Revenue | 2.94B+16.7% | 2.52B+60.6% | 1.57B+53.3% | 1.02B+6.8% | 958M+21.4% | |
| — | — | 1.02B+34.4% | 759M+5.6% | 719M+25.8% | ||
| Cost of revenue | 958M-7.5% | 1.04B+88.9% | 548M+107.9% | 264M+10.2% | 239M+10.0% | |
| — | — | 887M+67.0% | 531M-2.9% | 547M+18.9% | ||
| Research & development | 147M-10.1% | 164M+32.0% | 124M+69.8% | 73.0M-25.0% | 97.3M+15.2% | |
| Selling, general & administrative | 1.18B+20.1% | 981M+52.4% | 644M+49.0% | 432M+5.9% | 408M+15.1% | |
| Restructuring | — | 29.7M | — | — | — | |
| Amortization of intangibles | 118M-1.0% | 119M+133.9% | 51.0M+187.7% | 17.7M-4.3% | 18.5M+10.1% | |
| Provision for credit losses | 10.2M-39.8% | 17.0M+364.4% | 3.66M+365900.0% | -1.00K-100.1% | 1.20M-59.5% | |
| Operating income | 480M+189.1% | 166M+24.7% | 133M-41.6% | 228M+32.6% | 172M+54.3% | |
| Net interest income | — | -4.19M-120.8% | 20.1M+41.4% | 14.2M+53.1% | 9.30M-33.4% | |
| Other non-operating income | 3.41M+54.8% | 2.21M+203.1% | -2.14M-215.3% | 1.85M-78.1% | 8.45M-41.6% | |
| Pre-tax income | 605M+401.2% | 121M-27.0% | 165M-31.9% | 243M+34.7% | 180M+43.3% | |
| Income tax | 67.2M+278.8% | 17.7M-58.3% | 42.5M-19.5% | 52.9M+69.3% | 31.2M+32.2% | |
| 538M+422.3% | 103M-16.2% | 123M-35.4% | 190M+27.5% | 149M+45.9% | ||
| Net income to common | 538M+422.3% | 103M-16.2% | 123M-35.4% | 190M+27.5% | 149M | |
| $3.92+422.7% | $0.75-29.9% | $1.07-42.2% | $1.85+28.5% | $1.44+42.6% | ||
| EPS (basic) | $3.98+423.7% | $0.76-30.3% | $1.09-42.3% | $1.89+27.7% | $1.48+42.3% | |
| Weighted-avg shares (basic) | 135M-0.4% | 136M+20.0% | 113M+12.6% | 100M-0.3% | 101M+2.2% | |
| Weighted-avg shares (diluted) | 137M-0.6% | 138M+20.3% | 115M+11.7% | 103M-0.9% | 104M+2.6% | |
| Balance Sheet | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 2.13B-2.4% | 2.18B+13.7% | 1.92B+94.8% | 983M+13.7% | 865M+5.2% | ||
| Cash & equivalents | 526M-32.9% | 784M+67.9% | 467M+210.6% | 150M-22.1% | 193M-19.4% | |
| Short-term investments | 31.1M-70.6% | 106M+109.2% | 50.5M-82.9% | 296M+18.1% | 250M+33.6% | |
| Accounts receivable | 679M+21.7% | 558M+10.8% | 503M+136.0% | 213M+29.7% | 164M+16.1% | |
| Inventory | 759M+15.2% | 659M-22.3% | 848M+183.7% | 299M+26.2% | 237M+3.4% | |
| Prepaid expenses | 65.4M+31.8% | 49.6M+11.4% | 44.6M+112.3% | 21.0M+14.0% | 18.4M+3.6% | |
| 5.30B+1.0% | 5.25B+3.3% | 5.09B+145.0% | 2.08B+6.1% | 1.96B+16.5% | ||
| Property, plant & equipment | 564M+0.5% | 562M-4.3% | 587M+140.8% | 244M+10.2% | 221M+1.9% | |
| Operating lease right-of-use | 63.8M+28.5% | 49.6M-17.2% | 59.9M+900.9% | 5.99M+19.3% | 5.02M+5.9% | |
| Goodwill | 1.44B+0.2% | 1.43B-0.2% | 1.43B+626.5% | 197M+9.9% | 180M+14.7% | |
| Intangible assets | 745M-6.3% | 795M-14.0% | 925M+1354.4% | 63.6M-7.4% | 68.7M-21.0% | |
| Long-term investments | 71.8M+8.6% | 66.1M-12.3% | 75.4M-84.8% | 496M-11.8% | 562M+56.9% | |
| Deferred tax assets | 218M+131.7% | 94.2M+781.6% | 10.7M-78.1% | 48.8M+99.4% | 24.5M+270.3% | |
| Other non-current assets | 78.8M+4.9% | 75.1M-4.4% | 78.6M+110.6% | 37.3M+2.7% | 36.3M+13.4% | |
| 498M-41.8% | 856M+118.2% | 392M+146.4% | 159M+13.6% | 140M+16.0% | ||
| Accounts payable | 98.9M+31.6% | 75.1M+32.6% | 56.7M+57.0% | 36.1M+64.4% | 22.0M+20.6% | |
| Accrued liabilities | 334M+28.0% | 261M+8.4% | 240M+160.9% | 92.2M+1.1% | 91.2M+16.4% | |
| Deferred revenue | 27.7M+24.9% | 22.1M+20.5% | 18.4M+30.3% | 14.1M+17.3% | 12.0M+48.0% | |
| Short-term & current debt | 0.00-100.0% | 443M | — | — | — | |
| Current lease liability | 14.7M+43.8% | 10.2M-14.4% | 12.0M+371.9% | 2.54M+19.8% | 2.12M+13.5% | |
| Finance lease liability (current) | 348K+49.4% | 233K-50.9% | 475K | — | — | |
| 730M-32.1% | 1.07B-1.3% | 1.09B+373.6% | 230M+6.4% | 216M+24.6% | ||
| Non-current lease liability | 104M+24.3% | 83.6M-8.2% | 91.0M+2519.8% | 3.48M+18.3% | 2.94M+0.0% | |
| Operating lease liability (total) | 119M+26.4% | 93.8M-8.9% | 103M | — | 5.05M+5.2% | |
| Finance lease liability (total) | 784K+47.6% | 531K-34.6% | 812K | — | — | |
| Finance lease liability | 436K+46.3% | 298K-11.6% | 337K | — | — | |
| Deferred tax liabilities | — | 23.9M-71.7% | 84.4M+4645.4% | 1.78M-58.8% | 4.31M-30.4% | |
| Other non-current liabilities | 21.3M-0.9% | 21.5M-12.5% | 24.6M+137.8% | 10.3M-18.2% | 12.6M-14.0% | |
| 4.57B+9.5% | 4.18B+4.5% | 4.00B+116.5% | 1.85B+6.0% | 1.74B+15.6% | ||
| Additional paid-in capital | 3.17B+4.6% | 3.03B+5.6% | 2.87B+355.0% | 631M+13.9% | 554M+21.1% | |
| Retained earnings | 1.39B+20.4% | 1.15B+1.4% | 1.14B-8.3% | 1.24B+3.8% | 1.19B+14.3% | |
| Accumulated other comprehensive income | 15.3M+323.7% | -6.86M+32.7% | -10.2M+58.6% | -24.6M-263.7% | -6.77M-271.2% | |
| Total liabilities & equity | 5.30B+1.0% | 5.25B+3.3% | 5.09B+145.0% | 2.08B+6.1% | 1.96B+16.5% | |
| Shares outstanding (cover) | 135M-1.7% | 138M+1.6% | 135M+35.0% | 100M-1.2% | 102M+1.8% | |
| Cash Flow | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| 753M+44.7% | 521M+113.8% | 243M+36.4% | 178M-35.4% | 276M+39.0% | ||
| Depreciation & amortization | 277M+9.3% | 253M+74.1% | 146M+113.2% | 68.3M-2.3% | 69.9M+11.1% | |
| Intangible amortization | 118M-1.0% | 119M+133.9% | 51.0M+187.7% | 17.7M-4.3% | 18.5M+10.1% | |
| Share-based compensation | 49.8M-8.1% | 54.2M+2.7% | 52.7M+60.7% | 32.8M+7.3% | 30.6M+13.0% | |
| Deferred income taxes | — | -134M-130.1% | -58.2M-160.9% | -22.3M-26.5% | -17.6M-347.8% | |
| Change in receivables | 52.2M-33.2% | 78.1M+56.4% | 49.9M-1.8% | 50.8M+96.3% | 25.9M+342.1% | |
| Change in inventory | 17.6M-41.1% | 29.9M-57.5% | 70.3M+13.9% | 61.7M+415.8% | 12.0M-76.1% | |
| Change in payables | 8.49M-52.0% | 17.7M+224.2% | -14.2M-198.6% | 14.4M+291.4% | 3.68M+158.0% | |
| -355M-101.7% | -176M-158.1% | 303M+374.5% | -110M+70.6% | -376M-220.4% | ||
| Capital expenditure | 165M+42.7% | 115M+47.5% | 78.3M+5.7% | 74.0M+30.1% | 56.9M-10.6% | |
| Free cash flow | 589M+45.3% | 405M+145.2% | 165M+58.2% | 104M-52.4% | 219M+62.3% | |
| Acquisitions | 253M+1332.1% | 17.6M-94.0% | 296M+841.7% | 31.4M-8.9% | 34.5M+3.0% | |
| Purchases of investments | — | 114M+12.8% | 101M-76.0% | 420M-32.6% | 622M+178.4% | |
| Sales/maturities of investments | 63.9M+8.9% | 58.7M-75.6% | 240M-23.1% | 312M+37.0% | 228M+69.5% | |
| -679M-2352.2% | -27.7M+88.1% | -232M-110.8% | -110M-303.1% | 54.1M+240.0% | ||
| Long-term debt issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long-term debt repaid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common stock repurchased | 300M+250.2% | 85.8M-62.0% | 226M+56.1% | 144M | 0.00-100.0% | |
| Dividends paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| FX effect on cash | 22.4M+8702.0% | 255K-88.3% | 2.18M+391.8% | -747K+7.8% | -810K-193.6% | |
| Net change in cash | -258M-181.4% | 317M+0.1% | 317M+843.7% | -42.6M+8.0% | -46.3M-206.1% | |
| Income taxes paid | 98.9M-37.6% | 159M+57.6% | 101M+29.3% | 77.8M+72.8% | 45.0M+77.0% | |
| Valuation Ratios | as ofDec 31 ’25 | as ofDec 31 ’24 | as ofDec 31 ’23 | as ofDec 31 ’22 | as ofDec 31 ’21 | |
| Market cap | 11.8B+3.8% | 11.4B+85.2% | 6.14B-17.2% | 7.42B+1.1% | 7.33B+12.7% | |
| P/E | 22.0×-80.1% | 110.5×+184.0% | 38.9×-18.6% | 47.8×-2.8% | 49.1×-22.8% | |
| P/S | 4.0×-11.0% | 4.5×-9.8% | 5.0×-32.6% | 7.4×-2.9% | 7.7×-7.2% | |
| P/B | 2.6×-5.2% | 2.7×+85.7% | 1.5×-65.1% | 4.2×-0.2% | 4.2×-2.6% | |
| P/FCF | 20.1×-28.6% | 28.1×-41.0% | 47.6×-24.3% | 62.8×+88.0% | 33.4×-30.6% | |
| Earnings yield | 4.6%+403.1% | 0.91%-64.8% | 2.6%+22.8% | 2.1%+2.9% | 2.0%+29.5% | |
| FCF yield | 5.0%+40.0% | 3.6%+69.5% | 2.1%+32.1% | 1.6%-46.8% | 3.0%+44.1% | |
| Source filing | 10-K | 10-K | 10-K | 10-K | 10-K |
About this data
Source: GMED’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all GMED filings on SEC EDGAR → Not investment advice.